

Stanford Cancer Institute

# Cancer Cell Therapy

Version Date:  
September 6, 2023

## T-Cell Lymphoma


>18 yrs; Relapsed or  
Refractory Disease  
Second / Third Line


[CCT5041](#)  
Phase I  
Anti-CD70  
CRISPR-Cas9-  
Engineered  
TCells(CTX130)  
in Relapsed/  
Refractory T/B  
Cell  
Malignancies

PI: Weng  
Sponsor:  
CRISPR

**KEY**


 Pending

 Open for Enrollment

 Observational Study

 Optional Path

[Link](#) Trial Posting

 Enrollment on Hold

 Extension Study

 Immunotherapy